January 26, 2026
Built by a former cannabis regulator, Policy, Decoded helps operators read the policy terrain before it shifts beneath their feet.
Today’s edition starts with THC beverages moving from novelty to planogram as retailers expand the category and Washington stares down a November compliance cliff that could clear the shelf. We also track Congress pushing an FDA lane for hemp products, and Florida turning a signature fight into criminal enforcement with real ballot timing consequences.
This briefing is supported by our day job at THC Group, where we provide strategic counsel for policy and regulatory headaches, and by The Hybrid podcast with former regulators Shawn Collins and Erik Gundersen.
🥤 Shelf space meets a federal cap
🏛️ FDA lane on a deadline
🚨 Enforcement becomes leverage
Here we go again.
Start here — the day’s most important development, decoded for impact.
📌 What Happened: Hemp-derived THC beverages have moved from novelty to planogram, with liquor departments and national chains treating the category as a real growth driver during the deadest month of the alcohol calendar. Stew Leonard’s says it has expanded from fewer than 10 brands to roughly 75 in three years and is running about 25% ahead of last January, while Total Wine describes THC beverages as one of its fastest-growing sets. The products showing up in mainstream retail generally sit in the five to ten milligram range and are being merchandised like a sessionable alternative rather than an edible in a can. Retail momentum is now running into a hard federal constraint scheduled for November: a 0.4 milligram per container limit that would make most current beverage SKUs structurally noncompliant. Some brands are pausing planting, production commitments, and distribution expansion because the risk has moved from hypothetical to operational.
💡 Why It Matters: The federal cap introduces a date-certain compliance risk that propagates upstream through procurement, distribution, and insurance. Buyers and wholesalers manage this kind of deadline exposure for a living, and a November cliff changes behavior well ahead of enforcement. National retailers can tighten authorizations, slow resets, and delist products tied to a known federal cutoff. Distributors follow because warehousing inventory that ages into noncompliance creates its own liability. The market can constrict in spring and summer, months before November, through quieter moves that never make headlines. Politics shifts with the merchandising: once these products live in liquor aisles and big-box sets, they become a mainstream consumer protection story that legislators can touch without a crash course. Public health framing will carry the argument in committee rooms, backed by real failure modes like inconsistent dosing expectations, delayed onset, and packaging that reads like candy. The category’s discipline gap now matters at the federal level because high-potency formats and sloppy channels make it easier for Congress to govern the whole field with a blunt instrument.
🧠 THC Group Take: This category has something most cannabis-adjacent products never get: a mainstream on-ramp that looks and behaves like a regulated adult beverage. That is why the growth is real and why the political attention is arriving now. Congress remains unpredictable, and anyone who says they can call the exact landing spot is selling something, yet the direction of travel is clear: lawmakers need a framework that matches how consumers already shop and how retailers already merchandise. The industry has started doing the work that earns credibility, drawing sharper lines between disciplined, age-gated, low-dose beverage models and the products that created the backlash. It is also building allies that matter in Washington and in state capitols, including wholesalers, distributors, and large retailers with real leverage and a strong interest in a stable rulebook. That coalition work has to keep going, because constituents already treat these drinks as part of normal adult life, and electeds eventually follow where their voters spend money and time. The best near-term outcome looks like a governable lane that keeps responsible products on shelves and squeezes out the failure modes that made Congress reach for a hammer. The brands that win will be the ones that can hand a buyer, a regulator, and a cautious legislator the same simple story and back it up with paperwork.
Fast-moving headlines, flagged for what matters.
House lawmakers introduced the HEMP Act to build an FDA-centered framework for consumable hemp products as the federal THC timeline tightens. The bill sets a 21-plus baseline and leans on testing, labeling, facility registration, and packaging limits tied to youth appeal. It forces a deadline on cannabinoid standards, with default potency limits snapping in if FDA does not finalize rules within three years. Brands are already cheering because capital and retail shelf plans need a credible federal lane. The fight turns on definitions and enforcement authority, because that gate decides who survives the transition. (Marijuana Moment, MJBizDaily, Law360)
Florida Attorney General James Uthmeier is touting the arrest of a paid petition circulator accused of identity theft and fraudulent signatures tied to the Smart and Safe Florida initiative. Court records say the circulator used personal information from legitimate voters without consent, turning a signature-gathering dispute into a criminal case. The arrest follows referrals from local elections officials and fits into a broader probe that includes subpoenas and coordination with state law enforcement. This shifts the fight from ballot math to criminal process, which raises delay risk and muddies every remaining signature. The next pressure point is whether investigators treat this as a one-off or a ladder into broader operational discovery. (Florida Politics)
Virginia lawmakers advanced legislation that would finally stand up regulated adult-use sales after years of legal possession and home grow without a retail market. The framework points to an earliest retail start date of November 1st, giving regulators and capital a real planning horizon. The political temperature has shifted with Gov. Abigail Spanberger taking office after Glenn Youngkin’s repeated vetoes. The remaining fight sits in structure, license allocation, local control, and tax design. Virginia is deciding whether it wants an orderly market that can pull consumers out of the illicit channel or a slow build that leaves the gap in place. (Forbes)
Nebraska lawmakers introduced a cleanup bill drafted by the Medical Cannabis Commission to tighten the new medical program. The proposal would create a dedicated account funded by sales tax, stand up a patient registry, and build track-and-trace aimed at limiting diversion. Reform advocates argue the bill hands the commission too much discretion, including leverage to reshape qualifying conditions, limit product forms, and tighten physician requirements. Committee leadership points back to voter-approved measures that contemplated broad commission authority. The real question is governance: technical regulator or policy center of gravity once the market turns on. (Nebraska TV)
Michigan’s new 24% wholesale cannabis tax took effect January 1st, landing on the first transfer from grower or processor to retailer and stacking on top of existing retail taxes. The state is applying it in a market defined by oversupply and falling prices, leaving limited room for wholesalers to absorb the hit without renegotiating terms. Retailers now face a squeeze on promotions and basket pricing, and sustained increases risk sending value buyers back toward caregiver and gray-market channels. The rollout also creates compliance friction because businesses are interpreting mechanics in real time while the cash impact starts immediately. Michigan built its boom on low prices, and this tax tests whether the regulated channel can keep that promise while funding roads. (Michigan Chronicle)
Oregon cannabis prices remain depressed as oversupply keeps squeezing wholesale and retail margins across the state. Demand has held steadier than the headlines suggest, yet the math still punishes growers and smaller retailers who cannot scale their way out of thin spreads. Operators are watching for relief, including the possibility that federal rescheduling reduces 280E pressure and extends survival timelines. Oversupply still drives the core problem, so relief buys time rather than solves structure. The next shakeout rewards cash discipline and operational patience. (Oregon Public Broadcasting)
Missouri regulators fined multiple cultivation facilities for importing clones or tissue cultures from out of state after the state’s one-year startup window. Officials say some licensees treated the early period as continuing permission and kept importing genetics, colliding with tracking and in-state containment expectations. Settlements ranged from $50,000 to $500,000, with large multi-state operators taking the hardest hits. The enforcement message is clear: regulators will defend the integrity of the in-state supply chain even when it slows strain churn. Operators now have to build in-state breeding capacity or buy through local channels that may include competitors. (Missouri Independent)
A Michigan processor, Choice Labs, is expected to exit receivership in early February under new ownership after a year of court-supervised restructuring. Chicago Atlantic bought roughly $52 million of parent company debt and carried that position through the auction as the stalking horse bidder. The case traces back to lender withdrawal risk and fraud allegations tied to a minority owner, forcing a protective legal reset for the processor and its affiliated cultivator. The receiver says the business remained viable while the balance sheet and integration needed repair. This is what recapitalization looks like in cannabis when refinancing stays scarce and lenders become the buyers. (MMJDaily)
South Dakota lawmakers shut down a bill that would have let terminally ill patients keep using medical cannabis after entering a hospital or hospice. The House Health and Human Services Committee used a procedural deferral that ends the measure for the year. Supporters framed it as continuity of care for patients already authorized under state law. Hospital and nursing home groups pushed back on federal conflict risk and staff exposure. Families keep living with the same cliff, and access disappears at the door when care moves into an institution. (Marijuana Moment)
Arkansas dispensaries rang up about $291 million in medical cannabis sales in 2025, the state’s highest annual total since the program launched. The number clears the prior record from 2023 and reverses the 2024 dip that raised plateau questions. State figures also point to material sales tax revenue and strong volume, a reminder that this remains a volume business even in a mature medical program. The quiet story is durability and patient retention through a down year. Legislators will treat this revenue as part of the fiscal baseline, which raises the stakes of every future policy tweak. (MJBizDaily)
Cannabix says its marijuana breath test will land on the cover of AlcoPro’s 2026 catalog, putting a pre-launch product in front of law enforcement and corrections buyers. The marketing signal matters because impairment testing remains unsettled, and courts keep pressing what a breath result proves in real time. Cannabix is pairing breath collection with lab-grade analysis through Omega Laboratories to anchor credibility. Adoption will hinge on validation, standards, and chain of custody that agencies can defend as fair and job-relevant. If state agencies move early, expect labor groups and defense counsel to challenge the science and the process immediately. (TipRanks)
Federal authorities arrested Minnesota civil rights attorney and hemp operator Nekima Levy Armstrong after a protest disrupted a church service in St. Paul tied to an ICE official serving as pastor. Prosecutors moved quickly into federal charges, and reporting says they considered using the FACE Act. Cannabis leaders and operators responded publicly, warning the arrest chills community-facing advocacy in a market still building its regulated identity. The timing matters because Minnesota is trying to professionalize while keeping faith with its activist roots. Industry groups now face a real choice about how public they want to be when politics and enforcement collide. (GreenState)
A Washington Post opinion argues California’s legal cannabis market keeps getting undercut by organized theft and diversion, with licensed operators carrying security risk and thin protection. The piece spotlights a Santa Cruz cultivator who armed himself after repeated break-ins, then was arrested on attempted murder charges after a shootout with masked suspects. It also points to a structural driver: states still cannot legally move cannabis across state lines even as production outpaces in-state demand. That keeps incentives pointed toward leakage and organized crime. The question policymakers keep ducking is whether they want to keep asking licensees to absorb violence risk in a market that still runs like a semi-legal economy. (The Washington Post)
As a major snowstorm approached the Northeast, cannabis retailers reported a familiar pattern: customers stocking up before travel gets risky and deliveries slow down. Stores saw heavier foot traffic and bigger baskets as people treated pre-storm prep like a weekend supply run. Weather compresses shopping time and pushes consumers toward one-stop trips with predictable products. For operators, storms stress staffing, inventory depth, and security discipline when lines get long. The bigger tell is normalization, because cannabis is getting treated like any other regulated category when people brace for a few days indoors. (New York Post)
THC beverages are getting marketed as the middle lane between alcohol and edibles, with effects that can begin in the first half hour for many consumers and run for several hours depending on dose and metabolism. The faster ramp is part formulation and part format, since liquids can absorb differently than gummies and many brands use emulsions designed for quicker uptake. The risk is pacing, because consumers can stack servings early and get surprised when the peak arrives later. Regulators and retailers are watching because the product promise is predictability, and a few bad experiences can fuel potency caps and shelf pullback. The safest governing frame stays simple: low-dose servings, clear labeling, and consistent measurement. (Yahoo Lifestyle)
The deeper pattern behind today’s moves — and why it matters next.
From the hearing room to the comment section — we’re watching it all.
🏌️ Curaleaf is using the Waste Management Open as a culture moment, with a 19th-hole style activation that puts cannabis marketing in a premium, sports-adjacent lane. If it draws no heat, it becomes a template and more brands will follow the same playbook. (BevInfo Group)
🐶 A pending federal hemp crackdown is colliding with a quiet reality: pet owners already use hemp-derived cannabinoid products for anxiety, pain, and end-of-life comfort. If Congress narrows the lawful lane without a replacement pathway, the market shifts to less transparent channels where safety and consistency get worse. (Cannabis Business Times)
🌿 Terpenes are getting more attention as brands and consumers look beyond THC numbers to flavor, aroma, and perceived effect. The compliance line stays simple: describe what it smells and tastes like, and keep health claims out of the label. (Cannabis Now)
🍺 Boston Beer is placing chips in both directions: higher-strength tea for the drinker who stays in alcohol, and THC beverages in Canada for the drinker who does not. That is an incumbent planning around occasion shifts while U.S. rules remain unsettled. (FoodBev Media)